Nippon Shinyaku Co., Ltd. (TYO:4516)
3,396.00
-23.00 (-0.67%)
Nov 13, 2026, 3:30 PM JST
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 49.07B JPY in the quarter ending June 30, 2026, with 24.07% growth. This brings the company's total for the last twelve months to 180.29B, up 12.23% year-over-year. In the fiscal year ending March 31, 2026, Nippon Shinyaku had annual revenue of 170.77B with 6.58% growth. That makes Nippon Shinyaku the 7,119th largest company in the world by revenue and 724th in Japan.
Revenue (ttm)
180.29B
Revenue Growth
+12.23%
P/S Ratio
1.27
Revenue / Employee
78.08M
Employees
2,309
Market Cap
228.89B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Nippon Shinyaku breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 170.77B | 10.54B | 6.58% |
| Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
| Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
| Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
| Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sumitomo Pharma | 492.66B |
| Towa Pharmaceutical | 285.49B |
| Tsumura & Co. | 206.16B |
| Sawai Group Holdings | 203.79B |
| Mochida Pharmaceutical | 126.33B |
| KYORIN Pharmaceutical | 125.02B |
| Kissei Pharmaceutical | 97.08B |
| Zeria Pharmaceutical | 94.66B |